Literature DB >> 1375009

Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine.

T Björck1, L E Gustafsson, S E Dahlén.   

Abstract

Bronchial hyperresponsiveness can be demonstrated in asthmatic subjects by inhalation of adenosine, but the action of adenosine at the level of the human airway smooth muscle has received comparatively little attention. We have previously observed that bronchi isolated from one asthmatic patient contracted in response to adenosine. We have therefore, during the course of a 3-yr study, further characterized the effects of adenosine in bronchi prepared from surgical specimens of lung tissue of asthmatics and of nonasthmatics. Contraction responses were always studied in vitro the same day the tissues were obtained. Bronchi from asthmatics (19 strips from six patients) were more sensitive to adenosine than were bronchi from nonasthmatics (21 strips, seven patients). In contrast, there was no difference in sensitivity to histamine or leukotriene C4 between the two groups, nor was the maximal tissue contractility different. The contractile effect of adenosine was inhibited by the adenosine A1-antagonist 2-thio-[(1,3-dipropyl)-8-cyclopentyl]-xanthine as well as by the dual A1 and A2 antagonists 8-(p-sulfo)-phenyltheophylline and theophylline. The combination of leukotriene antagonism (receptor-antagonist ICI 198,615 or biosynthesis inhibitor MK-886) and histamine antagonism (antihistamines mepyramine and metiamide) blocked the contractile effects of adenosine, suggesting that adenosine acts indirectly by liberation of leukotrienes and histamine, possibly from mast cells. The findings of increased sensitivity to adenosine in bronchi from asthmatics to our knowledge represents the first evidence of increased bronchial reactivity in vitro in asthmatics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375009     DOI: 10.1164/ajrccm/145.5.1087

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  55 in total

1.  Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release.

Authors:  C I Ezeamuzie; E Philips
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 2.  Point: alterations in airway smooth muscle phenotype do/do not cause airway hyperresponsiveness in asthma.

Authors:  Susan J Gunst; Reynold A Panettieri
Journal:  J Appl Physiol (1985)       Date:  2012-04-19

3.  Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits.

Authors:  A el-Hashim; B D'Agostino; M G Matera; C Page
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

4.  Mechanism of adenosine-induced airways obstruction in allergic guinea pigs.

Authors:  Sandra Keir; Victoria Boswell-Smith; Domenico Spina; Clive Page
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

Review 5.  Airway smooth muscle growth in asthma: proliferation, hypertrophy, and migration.

Authors:  J Kelley Bentley; Marc B Hershenson
Journal:  Proc Am Thorac Soc       Date:  2008-01-01

Review 6.  Adenosine receptors and asthma.

Authors:  R A Brown; D Spina; C P Page
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

7.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

Review 8.  Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Clin Rev Allergy Immunol       Date:  2003-02       Impact factor: 8.667

Review 9.  Adenosine receptors and asthma in humans.

Authors:  C N Wilson
Journal:  Br J Pharmacol       Date:  2008-10       Impact factor: 8.739

Review 10.  Biophysical basis for airway hyperresponsiveness.

Authors:  Steven S An; Jeffrey J Fredberg
Journal:  Can J Physiol Pharmacol       Date:  2007-07       Impact factor: 2.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.